{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:20:05Z","timestamp":1780593605731,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s41030-024-00279-7","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:06:14Z","timestamp":1730109974000},"page":"469-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-8536","authenticated-orcid":false,"given":"Joshua R.","family":"Coulter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6112-0703","authenticated-orcid":false,"given":"Louis Edward","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Antipas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Montague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Terry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-5379","authenticated-orcid":false,"given":"Sally-Anne","family":"Dews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Ogden-Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4325-6439","authenticated-orcid":false,"given":"Colm","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-7268","authenticated-orcid":false,"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"279_CR1","first-page":"231","volume":"83","author":"DM Geynisman","year":"2013","unstructured":"Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013;83:231\u201341.","journal-title":"Discov Med"},{"key":"279_CR2","unstructured":"National cancer drugs fund list, national-cdf-list-v1.303.pdf(england.nhs.uk). Accessed 23 Apr 2024"},{"issue":"9","key":"279_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.2146\/ajhp070035","volume":"64","author":"J Aisner","year":"2007","unstructured":"Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health-System Pharmacy. 2007;64(9):S4\u20137.","journal-title":"Am J Health-System Pharmacy"},{"key":"279_CR4","unstructured":"Cancer Research UK, 2013\u20132017 data Lung cancer statistics. Cancer Research UK."},{"key":"279_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2147\/PPA.S443213","volume":"18","author":"B Hauber","year":"2024","unstructured":"Hauber B, Hand M, Hancock BC, Zarrella J, Harding L, Ogden-Barker M, Antipas AS, Watt SJ. Patient acceptability and preferences for solid oral dosage form drug product attributes: a scoping review. Patient Prefer Adherence. 2024;18:1281\u201397.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"279_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40273-022-01167-1","volume":"40","author":"IL Hollin","year":"2022","unstructured":"Hollin IL, Paskett J, Schuster ALR, Crossnohere NL, Bridges JFP. Best-worst scaling and the prioritization of objects in health: a systematic review. Pharmacoeconomics. 2022;40(9):883\u201399.","journal-title":"Pharmacoeconomics"},{"key":"279_CR7","doi-asserted-by":"publisher","DOI":"10.35844\/001c.13244","author":"LM Vaughn","year":"2020","unstructured":"Vaughn LM, Jacquez F. Participatory research methods\u2014choice points in the research process. J Particip Res Methods. 2020. https:\/\/doi.org\/10.35844\/001c.13244.","journal-title":"J Particip Res Methods"},{"issue":"6","key":"279_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17425247.2018.1472571","volume":"15","author":"S Stegemann","year":"2018","unstructured":"Stegemann S. Patient-centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness. Expert Opin Drug Deliv. 2018;15(6):619\u201327.","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"279_CR9","doi-asserted-by":"publisher","first-page":"237437352312137","DOI":"10.1177\/23743735231213767","volume":"15","author":"M Jalowsky","year":"2023","unstructured":"Jalowsky M, Hauber B, Scott MJ, Arkin S, Coulter JR, Watt SJ, Kelly LMG, Valentine A. Priority outcomes in sickle cell disease treatment: co-creation and implementation of a preference exercise with patients and caregivers to inform drug development. J Patient Exp. 2023;15(10):23743735231213770. https:\/\/doi.org\/10.1177\/23743735231213767.","journal-title":"J Patient Exp"},{"issue":"1","key":"279_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/074391569201100202","volume":"11","author":"A Finn","year":"1992","unstructured":"Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: the case of food safety. J Public Policy Marketing. 1992;11(1):12\u201325.","journal-title":"J Public Policy Marketing"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-024-00279-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00279-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T02:05:56Z","timestamp":1731981956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-024-00279-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["279"],"URL":"https:\/\/doi.org\/10.1007\/s41030-024-00279-7","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joshua Coulter, Louis Baig, Amy Antipas, Sally-Anne Dewes, Colm Doody, and Brett Hauber are employees of Pfizer and hold stock or stock options in Pfizer Inc. Michaela Ogden-Barker was an employee of Pfizer when this study was conducted. Debra Montague and Angela Terry have no conflicts to declare and were paid consultants of Pfizer in connection with the development of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. In the advisory board, the participants were advisors rather than research subjects. Each patient advisor was contracted individually, consistent with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice (). Participation in the advisory board was voluntary. Each contract outlined the objective and procedures of the advisory board, and specified remuneration, privacy, handling of personal data (consistent with EU and UK data protection regulations), and confidentiality. The extrapolation survey was determined not to require review by an NHS Research Ethics Committee (REC) using the NHS REC Decision Tool (). Participants who completed the extrapolation survey provided informed consent. With regard to publication, all participants and advisors were informed \u201cYour answers will be analysed together with information from other respondents. We may share or publish the results from this survey as overall summary data that includes information from all respondents combined. Your identity will remain confidential\u201d.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}